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Abstract: Objectives: Tumor necrosis factor alpha (TNF-) therapy has been implicated in the development of autoim-
mune diseases. Our aim was to describe three patients with spondyloarthropathies who responded to infliximab, a chi-
meric monoclonal antibody specific for TNF-, but developed new symptoms of spondyloarthropathies. In parallel, a re-
view of the literature on psoriasis induced by TNF- blockers was undertaken. 
Results: The first patient had been suffering from ankylosing spondylitis (AS) for more than 12 years. Infliximab induced 
a remission of AS, but he developed overt Crohn's disease two years after starting treatment. The second patient had AS 
for more than 20 years. Infliximab had an excellent effect on his AS, but he developed palmo-plantar psoriasis a few 
months after initiating therapy with the drug. The third patient, whose long-term and severe psoriasis had responded to in-
fliximab developed peripheral arthritis. A review of the literature revealed 63 cases of psoriasis induced by TNF- block-
ers (33 on Infliximab, 16 on Etanercept and 14 on Adalimumab). The underlying diseases were variable, including all the 
spectrum of conditions for which TNF- blockers are indicated. Patients developed psoriasis after a mean duration of 
treatment of 11 months. Interstingly, a substantial proportion of patients continued treatment with TNF  blockers, the 
psoriasis improving in a majority of cases under topical treatment only. 
Conclusion: While Infliximab may change the course of spondyloarthropathy, depressing the original symptoms it may 
uncover other occult aspects of these diseases. 
Keywords: Infliximab, spondyloarthropathy, crohn, psoriasis, anti-TNF. 
INTRODUCTION 
  Tumor necrosis factor alpha (TNF-) is an inflammatory 
cytokine that has been implicated in a variety of rheumatic 
and inflammatory diseases [1]. Infliximab, a chimeric mono-
clonal antibody specific for TNF-alpha, has been approved 
for the treatment of rheumatoid arthritis, Crohn's disease, 
ankylosing spondylitis, psoriasis and psoriatic arthritis [1]. In 
addition to dramatically changing the prognosis of these dis-
eases, the use of infliximab has been associated with the de-
velopment of a variety of autoimmune diseases such as sys-
temic lupus erythematosus (SLE), vasculitis as well as pso-
riasis [2, 3]. 
  Spondyloarthropathies are a family of related diseases 
which share striking points of similarity, such as negative 
tests for rheumatoid factor, absence of subcutaneous rheuma-
toid nodules, peripheral inflammatory arthritis, radiological 
sacroiliitis, tendency to familial aggregation, and  notably 
 a spectrum of overlapping features shared between the 
individual entities of this group [4]. As such, patients with 
one manifestation of spondyloarthropathy may develop fea-
tures of other spondyloarthropathies. We report three cases 
of patients who suffered from spondyloarthropathy related 
diseases who responded to treatment with infliximab but 
developed new manifestations of spondyloarthropathies in   
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spite of responding well to therapy, suggesting that TNF- 
blockade had stimulated overt manifestation of occult fea-
tures of their disease. 
METHODS 
  The three cases are reported with special emphasis on the 
clinical history and appearance of new symptoms with re-
spect to the use of Infliximab. A Medline database search 
using the terms “psoriasis infliximab etanercept adalimumab 
crohn arthritis” between January 1985 and august 2007 was 
performed. 
CASES 
  The 3 case reports are summarized in Table 1. 
CASE REPORT 1 
  The patient, a 33-year-old man, was diagnosed as anky-
losing spondylitis in 1995. There was no personal or familial 
history of psoriasis, inflammatory bowel disease or reactive 
arthropathy. He had failed several non-steroidal anti-inflam-
matory drugs (NSAIDs) and sulphasalazine due to lack of 
efficacy or side effects. He was commenced on low dose 
infliximab (3mg/kg) in June 2005 and experienced an im-
pressive improvement in his complaints. The pretreatment 
BASDAI score of 7 dropped to 3 and C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR) levels nor-
malized. On February 2007, 2 weeks after the last infusion of 
infliximab and while he was free of the musculoskeletal 
complaints, he developed abdominal pain and bloody diar-
rhea. A colonoscopy performed a few days later revealed   
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macroscopic and histological findings typical of Crohn's 
disease In retrospective he denied any past symptoms of 
IBD. The patient was treated with Mesalazine with resolu-
tion of his symptoms. He subsequently continued treatment 
with Infliximab at a dosage of 5 mg/kg. 
CASE REPORT 2 
  A 46-year-old man diagnosed as having ankylosing 
spondylitis in 1985. He ultimately developed stiffness of the 
entire spine, kyphosis of the thoracic spine and ankylosis of 
the cervical spine, but never experienced any extra-skeletal 
manifestation of the condition. Despite the advanced ana-
tomical status of the primary disease, activity was evident 
based on severe inflammatory back pain, the constant need 
for NSAIDS and increased ESR and CRP levels. In 2006, 
infliximab was prescribed. After the second infusion, he re-
ported a significant improvement in back pain and morning 
stiffness, accompanied by a decrease in ESR and CRP levels. 
Five months after starting this treatment, however, he devel-
oped a symmetric erythematous eruption of his palms and 
soles (Fig. 1) mandating cessation of treatment. Infliximab 
was exchanged with etanercept resulting in rapid resolution 
of the rash and excellent effect on symptoms of ankylosing 
spondylitis. 
 
Fig. (1). Plantar psoriasis in patient 2, after treatment with inflixi-
mab. 
CASE REPORT 3 
  A 46-year-old woman, having psoriasis more than 20 
years. The condition became progressively severe, and in-
volved more than 70% of the body most of the time. She had 
failed topical treatments, methotrexate, cyclosporine, neoti-
gazone and psoralen ultraviolet A (PUVA). Despite the se-
verity of the psoriasis, she never had musculoskeletal com-
plaints. In 2006, she was started on 5 mg/kg infliximab, with 
 
resolution of more than 75% of the psoriatic lesions. Three 
weeks after the sixth infusion, she developed arthritis of the 
small joints of the hands, shoulders and knees, without en-
thesitis or dactylitis. The laboratory tests revealed an in-
creased ESR and a positive antinuclear factor with normal 
anti-dsDNA. She nevertheless continued treatment with in-
fliximab, and experienced a significant improvement in both 
skin and musculoskeletal signs, lasting  for  3 weeks after 
each infusion. Treatment with Infliximab was subsequently 
stopped and switched to Etanercept. 
LITERATURE REVIEW 
  A Medline database search of relevant publications in the 
English literature between January 1985 and august 2007 did 
not reveal reports of Crohn’s disease or psoriatic arthritis 
following infliximab. However, more than 80 cases of pso-
riasis in patients treated with TNF- blockers have been de-
scribed [2, 3, 5-30]. Table 2 summarizes the clinical charac-
teristics of theses patients. 33 patients were on Infliximab, 16 
on Etanercept and 14 on Adalimumab. The underlying dis-
eases were variable, including the whole spectrum of condi-
tions for which TNF  blockers are indicated. Patients de-
veloped psoriasis after a mean duration of treatment of 11 
months. Table 2 reports the outcome of these patients. Inter-
estingly, a substantial proportion of patients continued treat-
ment with TNF  blockers, the psoriasis improving in a ma-
jority of cases under topical treatment only; implicating that 
cessation of therapy is not always indicated. 
DISCUSSION 
  Our 3 described patients underwent an impressive resolu-
tion of the original symptoms which warranted the admini-
stration of infliximab, but each went on to develop new 
spondyloarthropathic features while under this TNF- ther-
apy. All 3 patients had a protracted disease before being 
starting infliximab, without a hint for their eventual post-
infliximab additional symptoms, which make it much more 
likely that their de novo symptoms are related to the effect of 
the medication. 
  Several lines of evidence pointing to the immunomodula-
tory effects of TNF- blockades have been accumulating 
with the increasing use and longer follow-up of treatment 
with TNF- antagonists. Testimony of autoimmunity trig-
gered by TNF- blockers includes 92 reported cases of lu-
pus, 113 patients with vasculitis and 24 cases of interstitial 
lung diseases [2]. The ability of TNF- to induce autoanti-
bodies in a large proportion of patients was established in 
several studies [31-33]. 
  Our cases represent untoward immunomodulation trig-
gered by infliximab that had brought about the desired thera-
peutic effects on the existing disease symptoms for which it 
had been prescribed. The first case was a patient with long- 
 
Table 1.  Characteristics of the 3 Patients Reported 
 
  Age/Gender  Disease  Adverse Event  Time to Adverse Event  Outcome 
Case 1  33/M  AS  Crohn's  22 months  Resolution with mesalazine, Infliximab continued 
Case 2  46/M  AS  Psoriasis  5 months  Resolution after switching to etanercept 
Case 3  46/F  Psoriasis  Arthritis  7 months  Resolution after switching to etanercept  The Changing Face of Spondyloarthropathies Under TNF  Blockade  The Open Rheumatology Journal, 2008, Volume 2    55 
Table  2.  Clinical and Demographic Charasteristics of Pa-
tients Who Developed Psoriasis Under Treatment 
with TNF  Blocker 
 
Gender  57 Females, 33 Males, 3 UK 
Mean Age; Range  45;13-78 
Underlying disease  44 RA, 2 JRA,9 Crohn, 1 UC,  
17 AS (+4 Crohn), 2 Behcet,  
1 PsA,1 eosinophilic fasceitis, 1 uveitis  
Concomitant drugs  None 6, Methotrexate 22 Prednisone 8, 
Salazopyrine 5, Leflunomide 8,  
Azathioprine 3 
Infliximab  47 
Etanercept  17 
Adalimumab  16 
Family history of psoriasis  3 
Mean duration of  
treatment until  
psoriasis; SD 
11±12 
Infliximab: 9±10 
Etanercept: 7±7 
Adalimumab: 16±19  
Characteristics of  
psoriasis  
39 PPP, 38 Psoriasis vulgaris, 4 UK 
PPP - Pustular Palmoplantar Psoriasis, UK - Unknown. 
 
standing ankylosing spondylitis who acutely developed 
Crohn's disease. Endoscopic studies in patients with ankylos-
ing spondylitis have demonstrated the presence of intestinal 
inflammation in up to 60% of them, particularly in those 
with active peripheral joint disease
  [34]. One prospective 
follow-up of patients with juvenile onset disease who ini-
tially presented with peripheral rather than axial joint disease 
also showed that intestinal inflammation increases the likeli-
hood of progression to axial disease [35]. Our patient was 
probably predisposed to develop inflammatory bowel dis-
ease, but the fact that it developed with the introduction of 
infliximab, by itself indicated for Crohn’s disease, despite 
highly satisfactory control of his ankylosing spondylitis, 
strongly suggests a triggering effect of the drug. Interest-
ingly, etanercept, a soluble receptor of TNF- has been im-
plicated in the onset of 6 cases of Crohn's disease [36-39] -3 
of them in patients with ankylosing spondylitis [39]. The 
second case was a patient with very long-standing ankylos-
ing spondylitis who developed palmo plantar psoriasis 
shortly after beginning a course of infliximab. There have 
been several reports in the medical literature of new-onset 
psoriasis or worsening of pre-existing skin diseases in pa-
tients treated with TNF- inhibitors for psoriatic arthritis, 
rheumatoid arthritis, ankylosing spondylitis and inflamma-
tory bowel disease. Interestingly, infliximab is efficacious in 
treating skin psoriasis. A great proportion of the patients 
described in the literature presented with palmo-plantar pso-
riasis, although all forms of psoriasis were described [2, 3, 5-
30]. It has been suggested that palmo plantar psoriasis may 
be induced by an abnormal expression of TNF- in the ec-
crine palmar sweat gland and duct [40]. Although TNF- is a 
well-documented contributor to the psoriatic skin lesion, 
another important pathway for triggering common human   
 
autoimmune disease involves plasmacytoid dendritic cell 
precursors and type 1 interferon (INF) production. TNF- 
regulates INF- production and neutralization of endogenous 
TNF- may promote INF- production by plasmacytoid 
dendritic cells inducing psoriatic plaques [41]. Our third case 
was a woman with long-standing psoriasis who developed 
peripheral arthritis during treatment with infliximab. The 
differential diagnosis of this case includes infliximab-
induced lupus and psoriatic arthritis. The fact that the arthri-
tis subsequently responded to the infusion of infliximab and 
that the anti-dsDNA result was negative support the likeli-
hood of the seronegative arthritis having been triggered by 
infliximab. 
  Another plausible explanation for the undesired evolution 
of our three cases may involve the effect of TNF- antago-
nists on the risks of infection. TNF- blockers have been 
implicated in the reactivation of a variety of infectious dis-
eases, including mainly intracellular pathogens, such as My-
cobacterium tuberculosis and others [42]. Immune activation 
by bacteria was shown to have a
 crucial role in the develop-
ment of the disease in both reactive arthritis (ReA) and in the 
HLA-B27 transgenic rats model [43]. There is evidence that 
this is related to an abnormal persistence
  of intracellular 
pathogens, at least in
 ReA [31]. Recent studies indicate that 
other
 subtypes of SpA may also have an impairment of cer-
tain aspects
 of the innate immune defense, particularly with 
regard to the
  expression of scavenger receptors [44, 45]. 
However, whereas SpA
  has traditionally been associated 
with urogenital infection with
 chlamydia or gastrointestinal 
infections with Gram-negative
  pathogens, such as salmo-
nella, shigella, campylobacter, and yersinia [46],
  treatment 
with anti-TNF- blockers may affect the intestinal flora by 
inducing a change in the predominant manifestation of spon-
dyloarthropathies. 
Table 3.  Outcome of Patients Who Developed Psoriasis After 
Treatment with TNF  Blocker 
 
TNF Blocker   Outcome  
Infliximab (33 cases) 
 Continued 
 Discontinued 
  Switched to another TNF 
 Unknown   
 
22; 17 improved, 4 progressed, 2 UK 
20; 18 improved, 0 progress, 2 UK 
10; recurrence in 5 
4 
Etanercept (16 cases ) 
 Continued 
 Discontinued 
  Switched to another TNF 
 Unknown 
 
9; 8 improved, 1 persisted 
4; 4 improved 
2, recurrence in 1 
4 UK 
Adalimumab 
 Continued 
 Discontinued 
  Switched to another TNF 
 Unknown 
 
6; 3 improved, 1 progressed, 1 UK 
9; 8 improved, 1 progressed 
3 swithched to another TNF, 1 recurrence 
1 UK 
 
  In conclusion, in addition to the well-known autoimmune 
effects of anti-TNF- therapy, our cases suggest the possibil- 
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ity of other and untoward alterations of the course of spondy-
loarthropathies as a result of this treatment. In our patients, 
the trade-off was successful depression of one aspect of the 
disease at the expense of triggering a none less undesirable 
though occult facet of the spondyloarthropathic repertoire in 
an apparently predisposed patient. 
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